معرفی
John Hyngstrom, MD is an Associate Professor in the section of Surgical Oncology, division of General Surgery within the Department of Surgery at the University of Utah. He practices general surgical oncology with a focus on melanoma and sarcoma at the Huntsman Cancer Institute. Dr. Hyngstrom serves as the site primary investigator at HCI on multiple therapeutic cooperative group and industry sponsored clinical trials focusing on advanced melanoma and solid tumors. He is physician lead of the melanoma Clinical Trials Research Group and the clinical lead of the Melanoma Disease Center at HCI, as well as Surgery Chair of the Melanoma Working Group of the Southwest Oncology Cooperative Group through the NCI.
- Undergraduate: Bachelor of Arts from Washington University in St. Louis, Missouri
- Medical School: Doctor of Medicine from the University of Chicago Pritzker School of Medicine
- Residency: General surgery residency at the University of Chicago Medical Center
- Research Fellowship: Two-year clinical research fellowship in surgical oncology and tumor immunology at the Surgery Branch of the NCI/NIH in Bethesda, Maryland
- Specialty Fellowship: Complex general surgical oncology fellowship at the University of Texas MD Anderson Cancer Center
Dr. Hyngstrom's primary research interests focus on immunotherapy clinical trial development and survivorship issues in cancer patients. His work centers on improving care for patients with advanced melanoma and other solid tumors through innovative therapeutic approaches. A significant portion of his research involves developing and testing new immunotherapies, particularly for melanoma treatment. His clinical expertise in surgical oncology complements his research efforts, allowing him to translate laboratory findings into clinical applications that directly benefit patients.
Analysis of Dr. Hyngstrom's recent publications reveals a strong focus on melanoma treatment and immunotherapy. His work spans clinical trials of novel immunotherapies including oncolytic viruses, checkpoint inhibitors, and cancer vaccines. A significant theme is the development of neoadjuvant approaches to melanoma treatment, where therapy is given before surgery to improve outcomes. His research also addresses practical clinical questions regarding imaging utilization, management of immune-related adverse events, and detection of minimal residual disease. Much of his work involves multi-institutional collaborations through cooperative groups like SWOG and the Southwest Oncology Group.
Dr. Hyngstrom has been actively involved in mentoring surgical oncology fellows and residents at the University of Utah. His research has been supported by multiple industry-sponsored clinical trials and cooperative group studies through the NCI. As physician lead of the melanoma Clinical Trials Research Group at Huntsman Cancer Institute, he oversees a robust portfolio of clinical research studies focused on advancing melanoma treatment.
Dr. Hyngstrom leads the melanoma Clinical Trials Research Group and serves as the clinical lead of the Melanoma Disease Center at Huntsman Cancer Institute. His work involves close collaboration with medical oncologists, dermatologists, pathologists, and other specialists within multidisciplinary teams focused on improving melanoma care. He also serves part-time at the George Wahlen VA Hospital in Salt Lake City, extending his expertise to veteran patients.
